|
|
|
Alexion Signs Manufacturing Agreement
Swiss Lonza to produce antibody for commercial use
|
Business New Haven
1/20/2003
By: BNH
|
CHESHIRE - Alexion Pharmaceuticals has entered into a large-scale product supply agreement with Lonza Biologics for the long-term commercial manufacture of its C5 complement inhibitor antibody, eculizumab.
The Cheshire firm recently announced promising clinical results from clinical studies evaluating eculizumab treatment in membranous nephritis patients and patients with paroxysmal nocturnal hemoglobinuria. Additionally, a Phase IIB clinical study is under way with eculizumab in rheumatoid arthritis patients.
Financial terms of the agreement were not disclosed.
Explained David Keiser, Alexion's president and chief operating officer, “We have collaborated with Lonza for several years now with respect to the production of eculizumab for use in our clinical trials, and as we now gear our activities toward commercialization it was important to secure the manufacturing experience, expertise, state of the art facilities and capacity that Lonza is uniquely positioned to provide.”
Added Lonza CEO Markus Gemuend, “Lonza Biologics appreciates the confidence Alexion has shown in Lonza by choosing us to provide market supply of eculizumab from our new large scale facility in Portsmouth, N.H. We have been fortunate to have worked with Alexion on eculizumab from its early development to current clinical trial supply and look forward to continuing this collaboration.”
Lonza Biologics is part of Swiss-based Lonza Group, a chemical company operating 21 production and R&D facilities in nine countries. It employs 6,400 people worldwide and is the leading supplier of active chemical ingredients, intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
